ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2026
Increased cost of care and length of stay due to potentially preventable catheter-related infections in US inpatient data, 2022-2023.
Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluated differences in total cost of care (TCC) and length of stay (LOS) among patients with potentially preventable catheter-related infections (PPCRIs). Methods: A retrospective cohort analysis was conducted using the Premier Healthcare Database for calendar years 2022 and 2023. PPCRI cases and at-risk non-PPCRI cases were identified using the Solventum Potentially Preventable Complications (PPC) v38 grouper methodology, which identifies complications occurring during inpatient stays while applying clinical exclusions to avoid capturing progression of preexisting conditions. Each PPCRI case was matched to an at-risk non-PPCRI case based on age, race, sex, diagnosis-related group, and severity of illness. Results: PPCRI cases experienced significantly higher TCC and LOS in both study years. Mean TCC for PPCRI cases was approximately $162,000 in 2022 and $187,000 in 2023, compared with $44,000 and $40,000 for non-PPCRI cases, respectively ( Conclusions: PPCRIs are associated with substantial excess LOS, which drives markedly higher TCC. Targeted prevention of PPCRIs could yield savings of approximately $100,000 per case.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.